Friday, July 18, 2025 7/18/2025

Chimeric antigen receptor (CAR) Tregs for treatment of ocular inflammatory diseases

Award Number: R21EY036212
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2024
PERIOD OF PERFORMANCE END DATE: 04/30/2026

Group Awards By:

View Award Description

Chimeric antigen receptor (CAR) Tregs for treatment of ocular inflammatory diseases - Project Summary Two million uveitis new cases per year occur in the United States. The current treatment strategy is to suppress the immune system with corticosteroids or other medications that have serious side effects including an increased susceptibility to infection. After a patient achieves remission for one to two years, a slow taper of the medications can be attempted, and some patients can be completely tapered off medications and maintain durable remission. There is a strong correlation between the induction of regulatory T cells (Tregs) and achieving durable remission. Unfortunately, the current medications used to treat uveitis do not induce Tregs. Therefore, treatments that target Treg induction or a cell-based approach to delivery Tregs to a patient represents a novel therapy with lasting benefits. Chimeric antigen (CAR) T cells that target B cells have been used to treat B cell lymphoma, and more recently for the treatment of B cell mediated autoimmune diseases, such as systemic lupus erythematosus. CAR Treg cells have been designed to prevent an immune response against adeno associated virus (AAV), thus allowing for more effective gene therapy. We propose to demonstrate that CAR Tregs are effective in suppressing autoimmune uveitis. Our central hypothesis is that CAR Tregs effectively suppresses ocular inflammation. We have a unique opportunity to evaluate and develop ocular CAR Tregs with the experience in the Lee lab with experimental autoimmune uveitis (EAU), and the Keeler lab that has experience developing CAR Tregs. The Keeler lab has AAV-specific CAR Tregs on hand and has shown these are effective at suppressing inflammation. Therefore, we will determine if administration of AAV-specific CAR Tregs in combination with an intraocular injection of AAV is effective in suppressing EAU (Aim 1). We will also generate ocular antigen-specific CAR Tregs and evaluate the efficacy of these Tregs to suppress EAU. Completion of this project will provide the foundation for developing a novel therapeutic for autoimmune uveitis and could further be applied to any ocular disease with an inflammatory component.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $251,250 )
2025	2025	UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL	55 LAKE AVE N	WORCESTER	MA	01655	WORCESTER	USA	Vision Research	000	2	4/18/2025	NON-COMPETING CONTINUATION	$251,250
														Subtotal = $251,250

Issue Date FY: 2024 ( Subtotal = $209,375 )
2024	2024	UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL	55 LAKE AVE N	WORCESTER	MA	01655	WORCESTER	USA	Vision Research	000	1	4/16/2024	NEW	$209,375
														Subtotal = $209,375

Grand Total All Awards = $460,625

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Chimeric antigen receptor (CAR) Tregs for treatment of ocular inflammatory diseases

Award Number: R21EY036212

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2024

PERIOD OF PERFORMANCE END DATE: 04/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer